Different anti-VEGF regimens may not result in superior vision benefits compared with ranibizumab for neovascular age-related macular degeneration, according to a meta-analysis presented at the virtual American Society of Retina Specialists meeting.
“Although some studies have compared the efficacies of different anti-VEGF therapies for wet AMD, no single trial can draw comparison between every anti-VEGF agent and dosing regimen available,” Diana V. Do, MD, of Byers Eye Institute at Stanford University, said in her presentation.
Using a network meta-analysis approach, Do and
Uncategorized